

Please amend the application as follows:

Amendments to the Claims

This listing of claims will replace all prior versions and listings of claims in the application.

Listing of Claims

1. (Currently amended) A method of treatment of solid tumors in a human in need of said treatment, which comprises administering a therapeutically effective amount of ~~one or more~~ arsenic trioxide compounds, wherein said solid tumor is a tumor of the central nervous system that is selected from the group consisting of neuroblastoma, retinoblastoma, glioblastoma, and oligodendroglioma.

2. (Previously amended) The method of claim 1, wherein said solid tumor is a metastatic tumor.

3-10. (Canceled)

11. (Currently amended) The method of claim 1 or 2 wherein said arsenic compound is ~~selected from the group consisting of arsenic trioxide and Fowler's solution~~ administered in combination with a therapeutically effective amount of at least one other therapeutic agent.

12. (Previously amended) The method of claim 1 or 2 wherein the total daily amount administered is from about 10 µg to about 200 mg.

13. (Canceled).

14. (Currently amended) The method of claim 11 ~~4~~, in which said at least one other therapeutic agent is a chemotherapeutic agent or radiotherapeutic agent.

15. (Previously amended) The method of claims 1 or 2, in which said administration is made parenterally, topically, dermally, directly into the tumor or orally.

16. (Currently amended) The method of claim 11 ~~4~~, in which said at least one other therapeutic agent is selected from ~~the group consisting of~~ etoposide, cisplatin, carboplatin, estramustine phosphate, vinblastine, methotrexate, hydroxyurea, cyclophosphamide, doxorubicin, 5-fluorouracil, taxol, diethylstilbestrol, VM-26 (vumon), BCNU, all-trans retinoic acid, procarbazine, cytokines, and therapeutic vaccines.

17. (Previously amended) The method of claim 1 or 2, in which said administration is made via an implantation device.

18-20. (Canceled).

21. (Currently amended) The method of claim 1, wherein said arsenic trioxide is administered intravenously in a total daily dose of from 0.5 mg to 150 mg.

22. (Currently amended) The method of claim 1, wherein said arsenic trioxide is administered intravenously in a total daily dose of from 0.5 mg to 150 mg.

23. (Currently amended) The method of claim 1 wherein said arsenic trioxide is administered intravenously in a total daily dose of from 0.5 mg to 150 mg.

24-27. (Canceled).

28. (Previously amended) The method of claim 1 or 2, wherein the arsenic compound is administered orally.

29. (Previously amended) The method of claim 1 or 2, wherein the arsenic compound is administered as a pill or tablet.